소식

As the year winds down, we’re filled with gratitude for the incredible journey that was 2024 for VIVEbiotech.

VIVEbiotech will be an exhibitor at Phacilitate’s Advanced Therapies Week to be held in Dallas from January 20-23.

VIVEbiotech, a leading lentiviral vector Contract Development and Manufacturing Organization (CDMO), today announced a growth equity investment from Ampersand Capital Partners (“Ampersand”), a private equity firm specializing in the life sciences and healthcare sectors.

We’re thrilled to announce that our latest research paper entitled “Establishment and Characterization of a Stable Producer Cell Line Generation Platform for the Manufacturing of Clinical-Grade Lentiviral Vectors” has been published in the journal Biomedicines.

The European Society of Gene and Cell Therapy´s annual congress is in full swing.

VIVEbiotech is participating as a Silver Sponsor in Innovative Therapies Days, a 2-day conference that takes place every year in Besançon, in the Région Bourgogne-Franche-Comté in France.

As in several past editions, VIVEbiotech is participating in Cell & Gene Meeting on the Mesa.

Natalia Elizalde, our Chief Business Development Officer at VIVEbiotech, recently shared her expertise with GEN on the increasing demand for lentiviral vectors, of which we are experts at VIVEbiotech.

Natalia Elizalde, Chief Business Development Officer of VIVEbiotech, is participating in Phacilitate’s Advanced Therapies Europe conference.

For the seventh consecutive year and also for the next two, VIVEbiotech has been certified with the CIR – Crédit d´Impôt Recherche certificate.